Anti-nausea and anti-vomiting activity of cannabidiol compounds

Abstract

The present invention relates the use of certain cannabidiol derivatives and of their dimethyl heptyl homologs (CBD-DMH) in the treatment of nausea, in particular chemotherapy-induced nausea, and of anti vomiting activity. The present invention relates also to the use of said cannabidiol derivatives being part of a pharmaceutical composition.

1 . A method for the treatment of nausea and of vomiting, comprising administering to a subject an effective amount of a cannabidiol compound of general formula I.  
     
     
         2 . The method of  claim 1 , wherein the cannabidiol compound is used in particular in the treatment of chemotherapy-induced nausea.  
     
     
         3 . The method of  claim 1 , wherein the cannabidiol compound is a compound of formula II.  
     
     
         4 . The method of  claim 3 , wherein the cannabidiol compound is used in particular in the treatment of chemotherapy-induced nausea.  
     
     
         5 . The method of  claim 1 , wherein the cannabidiol compound is a cannabidiol homolog of formula III.  
     
     
         6 . The method of  claim 5 , wherein the cannabidiol compound is used in particular in the treatment of chemotherapy-induced nausea.  
     
     
         7 . The method of  claim 1 , wherein the cannabidiol compound of formula I is part of a pharmaceutical preparation being selected from the group consisting of a tablet, a capsule, a granule, and a suspension in a solution.  
     
     
         8 . The method of  claim 7 , wherein said pharmaceutical compound comprises in addition to the active ingredient an excipient selected from the group consisting of a carrier, a disintegrant, a lubricant, a stabilizer, a flavoring agent, a diluent, and another pharmaceutically effective compound.  
     
     
         9 . The method of  claim 8 , wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution prepared with natural or synthetic ionic or nonionic surfactants, or a combination of such cosolvent and micellar solutions.  
     
     
         10 . The method of  claim 3 , wherein the cannabidiol compound of formula II is part of a pharmaceutical preparation being selected from the group consisting of a tablet, a capsule, a granule, and a suspension in a solution.  
     
     
         11 . The method of  claim 10 , wherein said pharmaceutical compound comprises in addition to the active ingredient an excipient selected from the group consisting of a carrier, a disintegrant, a lubricant, a stabilizer, a flavoring agent, a diluent, and another pharmaceutically effective compound.  
     
     
         12 . The method of  claim 11 , wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution prepared with natural or synthetic ionic or nonionic surfactants, or a combination of such cosolvent and micellar solutions.  
     
     
         13 . The method of  claim 5 , wherein the cannabidiol homolog of formula III is part of a pharmaceutical preparation being selected from the group consisting of a tablet, a capsule, a granule, and a suspension in a solution.  
     
     
         14 . The method of  claim 13 , wherein said pharmaceutical compound comprises in addition to the active ingredient an excipient selected from the group consisting of a carrier, a disintegrant, a lubricant, a stabilizer, a flavoring agent, a diluent, and another pharmaceutically effective compound.  
     
     
         15 . The method of  claim 14 , wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution prepared with natural or synthetic ionic or nonionic surfactants, or a combination of such cosolvent and micellar solutions.